Stayble Therapeutics
0,398
SEK
+3,11 %
STABL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Vær den første som følger denne virksomhed
+3,11%
-33,67%
-39,24%
+46,32%
+31,35%
+26,35%
-93,73%
-
-94,68%
Stayble Therapeutics operates in the pharmaceutical industry. The company specializes in research and development of injection treatments for pain caused by herniated discs. The drug candidates are developed and based on a proprietary technological platform. Most operations are found in the Nordic market and the company has its headquarters in Gothenburg.
Læs mereMarkedsværdi
17,4 mio. SEK
Aktieomsætning
54,36 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
25.2
2025
Årsrapport '24
ViserAlle indholdstyper
Stayble Therapeutics' STA363 receives positive phase 1b results
Stayble Therapeutics: Stayble's CEO to BioStock: "We are looking forward to new study results in 2024"
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools